Claudia Angela M. Fulgenzi
@fulgenziclaudia
Medical Oncologist; PhD student; Imperial College, London; University Campus Bio-Medico interested in HCC; KS and HIV-induced malignancies
ID: 1385862696520798216
24-04-2021 07:46:41
104 Tweet
432 Followers
440 Following
Antonio D'Alessio brings home to the team an exceptional result following for the third year running Claudia Angela M. Fulgenzi and Petros Fessas in a long series of ILCA awards - beyond proud 🥲🔥
Grateful for the occasion to share ideas with friends and colleagues! See you at #ESMO23 Annual Conference in Madrid. Antonio D'Alessio Alessio Cortellini Andrea Napolitano @A_CammarotaMD David James Pinato 🇺🇦 Dr Ravindhi Murphy
What a privilege to hear from Hanahan his views on the Hallmarks of cancer in 2023 🔬 more than two decades in the making - who would've guessed in 2000 that polymorphic microbiomes would become a hallmark of cancer? ESMO - Eur. Oncology #ESMO23 Claudia Angela M. Fulgenzi
.Andrea Napolitano giving us updates on the latest clinical trials in #leiomyosarcoma Nice crossword puzzle!!😄
As ‘23 draws to an end and out of office reply is solidly on I’d like to celebrate my promotion to Clinical Reader/Associate Professor👨🎓 Imperial College London UPO - Università Busy HCC agenda in ‘24 Starting strong with a joint vision from 2 institutions willing to make a difference 👨🔬
Honoured to share our News&Views published on Nature Medicine today 🗞️ our thoughts on adjuvant sintilimab and rego+nivo (RENOBATE trial) 🩺 ICIs in HCC are getting "here, there, and everywhere"🌍 David James Pinato 🇺🇦 Claudia Angela M. Fulgenzi nature.com/articles/s4159…
Immunotherapy is truly changing all stages of hepatocellular carcinoma. Honoured to have been tasked to make sense of this change with Antonio D'Alessio Claudia Angela M. Fulgenzi for Nature Medicine Surgery and Cancer UPO - Università nature.com/articles/s4159…
Two new studies hint at a greater understanding of how to apply #immunotherapy in early and advanced #HCC, but also highlight complexities and gaps in this rapidly evolving field. News & Views from David James Pinato 🇺🇦 & colleagues @ImperialCollege UPO - Università nature.com/articles/s4159…
Delighted to have hosted our first Imperial College London HCC Masterclass with an outstanding faculty Bernardo Stefanini Antonio D'Alessio Lorenza Rimassa Irene Bargellini Ciro Celsa Claudia Angela M. Fulgenzi Pasquale Lombardi at Surgery and Cancer
I am beyond proud to have got a GOYIA by Conquer Cancer, the ASCO Foundation to support our research on HIV-associated HCC. This would have never been possible without the support of my team and my inspiring PI David James Pinato 🇺🇦 at Imperial College London ! Looking forward to generating new data for our patients!
One of the brightest minds 🔥 in Cancer Research Claudia Angela M. Fulgenzi came tip toeing to London a few years back. I knew she was clever 🧚♂️ and the world now knows too 🌎 Surgery and Cancer Imperial College AHSC NIHR Imperial BRC thanks to Mark Bower and Rafeh Naqash, MD for mentorship and support 🥇
Excited to present my oral communication at #EASLCongress on Hepatic decompensation as determinant of mortality in patients with #HCC treated with atezo/bev and the role of etiology of liver disease #livertwitter EASL Education EASLnews UniPa PROMISE Imperial College London
Now on HEPATOLOGY Journal our last paper on hepatic decompensation during immunotherapy for #HCC. Lack of effective etiological therapies disadvantages pts w/ non-viral HCC. Thanks to David James Pinato 🇺🇦 Giuseppe Cabibbo Claudia Angela M. Fulgenzi Antonio D'Alessio Bernardo Stefanini Giulia Francesca Manfredi Bernhard Scheiner UniPa
Thank you Enrique Soto for spending time to comment on our paper, and for giving us the occasione to provide further clarifications for the other readers. The baseline characteristics were indeed imbalanced between the 2 groups. This is why IPTW was done.
